SGLT2抑制剂与他汀联用不增加肌毒性报告风险:一项失衡分析
基于FAERS 2013至2021年数据,共识别456例肌病和77例横纹肌溶解报告涉及SGLT2抑制剂与他汀联用。联用未增加肌病(ROR 0.79,95%CI 0.70-0.89)或横纹肌溶解(ROR 0.58,95%CI 0.41-0.83)报告风险,高交互潜力药物对在控制刺激报告后信号消失。
要点
- SGLT2抑制剂与他汀联用未增加肌病或横纹肌溶解报告风险。
- 高交互潜力药物对初始信号在控制刺激报告后消失。
- 临床无需因肌毒性担忧而避免SGLT2抑制剂与他汀联用。
核心结论
- SGLT2抑制剂与他汀联用未增加肌毒性报告风险,特定药物对亦无增加。
研究设计与样本
- 基于FAERS 2013至2021年数据的失衡分析,以全数据集为参照。
- 计算ROR(95%CI)、Ω收缩测量和PRR扩展法评估报告失衡。
主要发现
- 共456例肌病和77例横纹肌溶解报告涉及SGLT2抑制剂与他汀联用。
- 肌病ROR 0.79(95%CI 0.70-0.89),横纹肌溶解ROR 0.58(95%CI 0.41-0.83)。
- Ω收缩测量为负值,PRR扩展法仅满足一项标准。
- 高交互潜力药物对(卡格列净-瑞舒伐他汀、恩格列净-瑞舒伐他汀)出现横纹肌溶解潜在信号,控制刺激报告后消失。
临床怎么用
- 临床可依据现有证据不因肌毒性风险而避免SGLT2抑制剂与他汀联用。
局限性
- 研究为基于自发报告数据的失衡分析,不能确立因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Recent case reports have suggested that sodium-glucose co-transporter 2 (SGLT2) inhibitors may interact with statins to increase their risk of myotoxicity. We assessed the risk of myotoxicity reporting associated with concomitant use of SGLT2 inhibitors and statins. METHODS: We queried the US Food and Drug Administration Adverse Event Reporting System (FAERS) from 2013 to 2021 for reports including SGLT2 inhibitors, statins or both. We estimated several measures of disproportionate reporting of myopathy and rhabdomyolysis associated with concomitant use of SGLT2 inhibitors and statins: reporting odds ratio (ROR) with 95% confidence interval (CI), Ω shrinkage measure (safety signal if >0) and an extension of the proportional reporting ratio (PRR) (two-criteria set, safety signal if both criteria are met), using the full FAERS dataset as the reference set. In sensitivity analyses, we focussed on specific SGLT2 inhibitor-statin pairs with higher interaction potential (canagliflozin-rosuvastatin, empagliflozin-rosuvastatin) and accounted for stimulated reporting. RESULTS: There were 456 myopathy and 77 rhabdomyolysis reports involving both an SGLT2 inhibitor and a statin. Concomitant use of SGLT2 inhibitors and statins was not associated with an increased risk of myopathy (ROR 0.79, 95% CI 0.70 to 0.89) or rhabdomyolysis (ROR 0.58, 95% CI 0.41 to 0.83) reporting. For both outcomes, the Ω shrinkage measure was negative and only one criterion of the PRR extension was met. SGLT2 inhibitor-statin pairs with higher interaction potential yielded potential signals for rhabdomyolysis; these signals disappeared after accounting for stimulated reporting. CONCLUSION: There was no increased risk of myotoxicity reporting associated with concomitant use of SGLT2 inhibitors and statins or for specific drug pairs.
引用
- Gravel CA, Krewski D, Mattison DR, et al. Concomitant use of statins and sodium-glucose co-transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysis. Br J Clin Pharmacol. 2023. PMID: 36912450. doi:10.1111/bcp.15711
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。